ERBB2 and breast carcinoma: In a prospective, double‐blind, randomised trial of carvedilol effects in preventing chemotherapy‐induced cardiotoxicity, the authors intended to assess the effectiveness of carvedilol in an HER‐2‐negative breast cancer group treated with anthracycline, cyclophosphamide and taxane.